News
2023.12.18
| Possessing pre-stage human genomics and microbiome data
Dx&Vx is developing a medical data platform using AI technology from LG CNS and Google.
Dx&Vx recently announced on the 18th that it has signed a joint development agreement for a medical data platform utilizing Google's platform and AI technology through LG CNS. This marks the first collaboration between LG CNS and a domestic pharmaceutical and bio company.
Dx&Vx plans to launch an AI-based digital medical data platform through this joint development. LG CNS and Google DeepMind will provide the necessary artificial intelligence (AI) and big data technology for platform development. LG CNS is a partner and key service provider for Google Cloud.
Dx&Vx plans to expand its service network to the global market by utilizing a cloud-based medical data platform, catering to pharmaceutical companies, biotech firms, medical institutions, and research organizations that require specific genomic information or analysis.
Dx&Vx holds over 440,000 genomic analysis data, making it the largest dataset in Korea. This data encompasses nearly all stages of human genomics, including pre-implantation embryo genomes, products of conception, fetal cell-free DNA, amniotic fluid cells, neonates, adults, cancer cells, and microorganism data, serving as clinical data for medical diagnostics.
The dataset from Dx&Vx includes clinical data not only from healthy individuals but also from patient populations. This dataset is highly reliable and scalable, making it valuable for the discovery of biomarkers, elucidating the mechanisms of action, and developing therapeutic interventions for various research areas, including cancer cell development stages, rare disease studies, and infectious disease research.
A representative from Dx&Vx stated, "Currently, our company is incorporating artificial intelligence (AI) into various drug development projects to enhance the success potential of drug development. Simultaneously, we are expanding collaborations with IT companies domestically and internationally to extend related services." They further mentioned, "This joint development is expected to be a turning point for DXVX to grow into a global medical data company."
Dx&Vx plans to enhance collaboration with LG CNS and Google Cloud, starting with joint development, to further develop and advance healthcare solutions through an upgraded medical data platform.
Recently, the global pharmaceutical company GSK invested $300 million in the genetic analysis company 23andME for drug development using genomic information. Additionally, the Korea Biotechnology Industry Organization anticipates that the global genomics market will grow to $13.55 billion by 2024.
Source: Medical Times